The author of this post is John Mihaljevic, CFA, editor of Downside Protection Report .
So far we have focused on finding good stocks to buy and bringing them to you. In doing so, we have assembled a portfolio of ideas that has trounced the broader market (see scorecard on page 8 ). As our featured ideas hopefully make money for you, the question of when to sell becomes increasingly important.
Knowing when to sell a stock that has outperformed is no small task. The danger is dual: We can either sell too early, foregoing future gains; or we can sell too late, giving back the gains we have enjoyed on paper. There are additional wrinkles that complicate the decision to sell, including taxes and broader portfolio considerations.
Selling too early is a common “mistake” of value investors. While we make money on undervalued stocks that become less undervalued, we also frequently “leave money on the table.” Avoiding this predicament is difficult, perhaps even impossible — for it’s the same value-driven mindset that gets us to buy an undervalued company and to sell it when it trades closer to fair value. If we could hold onto a stock as it rises in price from fairly valued to overvalued, we might lack the mindset that allows us to buy the same stock at a bargain price in the first place.
Selling too late is rarer among value investors, but the danger exists nonetheless. We have a tendency to hang onto something that’s been good to us — a winning stock falls into this category. We may become emotionally attached or view a stock as our idea. The pain of selling and then seeing someone make more money from our idea might be too much to bear, influencing us to hold onto a company too long. There’s also the danger of keeping losers around merely because we want to break even. Facts, rather than “mental accounting,” should dictate the timing of a sale.
This brings us to two companies that we’re putting on the sell list this month — PDL BioPharma (PDLI) and Sierra Wireless (SWIR). Whether or not to sell is a “good problem” in each case, as PDLI shares have gained 15% since we featured them in our July 13th issue, while SWIR has gained 192% since March 23rd .
In the case of PDLI, while our analysis remains intact, one of the key validations of our work is no longer in place: Seth Klarman’s investment. When a superinvestor like Seth Klarman of The Baupost Group sells a company we own, the question must be, “How confident are we that we either know more than Klarman, or that our judgment is superior to his, or that he was selling for non-fundamental reasons?” In the case of PDLI, prudence requires us to take our gain and move on.
In the case of Sierra Wireless, we have obviously enjoyed a strong gain in a short time, and we hope you have as well. We simply cannot make a no-brainer valuation-driven case for Sierra any longer, even as the company has many other things going for it.
Finally, just as with buying a stock, the decision to sell must be driven by your own particular circumstances. There may be tax or other considerations that make holding onto a stock the correct decision, even if the valuation gap has narrowed.
Start 30-day FREE trial of Downside Protection Report .
Mihaljevic on Value Investors' Dilemma: When To Sell A Winner? DOWNSIDE PROTECTION REPORT With Edited by the Research Team of “Confronted with the challenge to distill the secret of sound investment into three words, we venture the motto: Margin of Safety.” —Ben Graham August 30, 2009 Dear Fellow Idea Seekers, So far we have focused on finding good stocks to buy and bringing them to you on t hese p ages. We h ave a ssembled a por tfolio o f i deas t hat has t rounced t he broader m arket ( see s corecard o n p age 8 ). A s o ur f eatured i deas h opefully make money for you, the question of when to sell becomes increasingly important. Knowing when to sell a stock that has outperformed is no small task. The danger is dual: We can either sell too early, foregoing future gains; or we can sell too late, giving back the gains we have enjoyed on paper. There are additional wrinkles that complicate the decision to sell, including taxes and broader portfolio considerations. Selling t oo ear ly is a co mmon “m istake” o f value i nvestors. W hile we make money o n undervalued stocks t hat b ecome l ess undervalued, w e also f requently “leave money o n t he t able.” Avoiding t his p redicament i s d ifficult, perhaps e ven impossible — for i t’s t he same value-driven m indset that ge ts us t o buy an undervalued company and to sell it when it trades closer to fair value. If we could hold onto a stock as it rises in price from fairly valued to overvalued, we might lack the mindset that allows us to buy the same stock at a bargain price in the first place. Selling too late is rarer among value investors, but the danger exists nonetheless. We have a t endency t o ha ng onto s omething t hat’s b een g ood t o us — a winning stock falls into this category. We may become emotionally attached or view a stock as our idea. The pain of selling and then seeing someone make more money from our idea might be too much to bear, influencing us to hold onto a company too long. There’s also the danger of keeping losers around merely because we want to break even. Facts, rather than “mental accounting,” should dictate the timing of a sale. This brings us to two companies that we’re putting on the sell list this month — PDL BioPharma (PDLI) and Sierra Wireless (SWIR). Whether or not to sell is a “good p roblem” i n each cas e, as P DLI s hares h ave g ained 1 5% s ince we f eatured them in our July 13th issue, while SWIR has gained 192% since March 23rd. In the case o f P DLI, while o ur a nalysis r emains intact, o ne o f t he ke y va lidations o f o ur work is no longer in place: Seth Klarman’s i nvestment. W hen a superinvestor like Seth Klarman of The Baupost Group sells a company we own, the question must be, “How confident are w e t hat w e either know more t han K larman, o r t hat o ur judgment is superior to his, or that he was selling for non-fundamental reasons?” In the case of PDLI, prudence requires us to take our gain and move on. In the case of Sierra W ireless, we have o bviously en joyed a s trong gain in a s hort ti me, and we hope you have as well. We simply cannot make a no-brainer valuation-driven case for Sierra any longer, even as the company has many other things going for it. Finally, just as with buying a stock, the decision to sell must be driven by your own p articular circumstances. T here may b e tax o r o ther c onsiderations that make holding onto a stock the correct decision, even if the valuation gap has narrowed. Sincerely, John Mihaljevic, CFA Managing Editor, The Manual of Ideas john@manualofideas.com Stocks We’re Buying This Month (Nasdaq: (Nasdaq: ……………… p. 2 ………………… p. 4 Also Inside Downside Protection Screens Top 10 companies trading below net cash ……… p. 6 trading below tangible book … p. 7 buying back their own stock … p. 7 See how we’re doing …………… p. 8 Scorecard About Downside Protection Report Our mission is to uncover stocks with a large margin of safety and bring them to you once a month. John Mihaljevic, editor, is a fund manager, former banker and analyst. He is a member of Value Investors Club, an exclusive community of top money managers, and has won the Club’s prize for best investment idea. John is a trained capital allocator, having studied under Yale chief investment officer David Swensen and served as research assistant to Nobel laureate James Tobin. John holds a BA in Economics, summa cum laude, from Yale and is a CFA charterholder. He resides in New York City with his wife and two kids. Stock Market Cheapness Snapshot % of U.S. stocks All MV> trading for less than… stocks $1bn …net net current assets 3% 0% …net cash 4% 1% …tangible book value 20% 6% …5x trailing EPS 3% 1% Data as of August 28, 2009. DOWNSIDE PROTECTION REPORT is published monthly by BeyondProxy LLC, P.O. Box 1375, New York, NY 10150. Website: www.manualofideas.com. Email: support@manualofideas.com. Please email or call if you have any subscription questions. Managing Editor: John Mihaljevic. Subscription $149 per year. © Copyright 2009 by BeyondProxy LLC. All rights reserved. Photocopying, reproduction, quotation, or redistribution of any kind is strictly prohibited without written permission from the publisher. This newsletter bases recommendations and forecasts on techniques and sources believed to be reliable in the past and cannot guarantee future accuracy and results. BeyondProxy’s officers, directors, employees and/or principals (collectively “Related Persons”) may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated in this newsletter. John Mihaljevic, Chairman of BeyondProxy, is also a principal of Mihaljevic Capital Management LLC (“MCM”), which serves as the general partner of a private investment partnership. MCM may purchase or sell securities and financial instruments discussed in this newsletter on behalf of the investment partnership or other accounts it manages. It is the policy of MCM and all Related Persons to allow a full trading day to elapse after the publication of this newsletter before purchases or sales of any securities or financial instruments discussed herein are made. Use of this newsletter and its content is governed by the Terms of Use described in detail at www.manualofideas.com/terms.html. SCORECARD Performance of Past Monthly Picks versus S&P 500 * On this page, we provide a quick update on past featured investments and let you know if it’s time to sell. (sorted by date of initial write-up) Featured Price Greenlight Capital Re / GLRE HOLD Valuation gap has narrowed, but we continue to like David Einhorn's investment strategy and portfolio. EchoStar / SATS HOLD Tivo litigation increases downside risk, but shares remain cheap. Microsoft / MSFT BUY Trades at discount to sum-of-parts valuation of business units. Capital Southwest / CSWC BUY Trades at wide discount to estimated fair value of investment portfolio. K-Swiss / KSWS BUY Trades close to tangible book value, despite good normalized economics and excellent management. Harvest Natural Resources / HNR BUY Shares trade at material discount to estimated fair value. Gravity Co. / GRVY BUY Shares trade below net cash despite major profitability inflection point. MI Developments / MIM BUY Shares trade at steep discount to fair value of real estate holdings. WellCare Health Plans / WCG BUY Shares trade close to net cash despite profitable operations. Kenneth Cole Productions / KCP BUY Shares trade at discount to estimated fair value. KHD Humboldt Wedag / KHD BUY Shares trade close to adjusted net cash; business is nearly “free.” Contango Oil & Gas / MCF BUY Trades at big discount to PV-10 valuation using NYMEX strip pricing. Closed Out Positions: Featured Price Date Crawford (CRD-A, CRD-B) (pair trade) Sierra Wireless (SWIR) SELL Gap to fair value has narrowed materially, adversely affecting the riskreward tradeoff of holding the shares. PDL BioPharma (PDLI) SELL Klarman’s sale makes us more cautious on the outlook for royalties and legal challenges to PDLI’s patents. $2.89** 2/9/09 Closed Out Price Date $1.02** 6/28/09 Price Change Absolute Annualized +65% +271% S&P 500 Change Abs. Ann. +6% +15% $10.85 Date 12/5/08 Latest Price as of 8/28/09 $18.37 Price Change +69.3% S&P 500 Change +17.6% $14.84 $19.71 $87.69 1/16/09 1/16/09 2/9/09 $19.27 $24.68 $77.53 +29.9% +25.2% -11.6% +21.5% +21.5% +18.9% $7.80 3/20/09 $9.97 +27.8% +34.8% $3.51 $0.95 $8.64 $19.04 $7.00 $8.28 $40.80 4/14/09 4/14/09 5/21/09 5/21/09 6/26/09 6/26/09 7/13/09 $5.24 $1.70 $13.66 $25.09 $10.02 $9.78 $45.48 +49.3% +78.9% +58.1% +31.8% +43.1% +18.1% +11.5% +22.6% +22.6% +15.9% +15.9% +12.6% +12.6% +14.7% $2.89 3/20/09 $8.45 8/28/09 +192% +1,039% +35% +97% $7.88 7/13/09 $9.06 8/28/09 +15% +203% +15% +198% * We measure the performance of the S&P 500 Index by the price changes of the S&P Depositary Receipts (SPY), which is an investable vehicle for the S&P 500. ** Represents spread rather than market price. Percentage return represents percentage narrowing of arbitrage spread. DOWNSIDE PROTECTION REPORT — August 30, 2009 Edited by the Research Team of The Manual of Ideas www.manualofideas.com 8 FREQUENTLY ASKED QUESTIONS Some of your top picks fell sharply in price before you picked them. How can you assert that a stock that has fallen precipitously has strong downside protection? Our assessment is based on protecting your capital from this point forward. It is quite unlikely that we would have recommended the same stock a year ago, as it may not have passed our stringent downside protection criteria. At higher prices, the shares most likely did not offer the “margin of safety” they provide today. The price decline has lowered investment risk rather than increased it. Are you saying that the stock price will not decline from this point forward? No. While we expect the stock to exhibit below-average downside, almost anything is possible in the stock market in the short term. As a result, you should never lever up to buy a stock, even if we judge it to have strong downside protection. We use the latter term to refer primarily to the risk that your capital will be permanently impaired. While our analysis gives us high conviction that you will not suffer permanent loss, our judgment will not always be correct. What criteria do you use to determine that a stock has “superior downside protection”? First and foremost, we want the stock to trade at a large discount to our appraisal of fair value. Such appraisal can be based either on the value of the company’s assets, including cash and real estate, or on the present value of estimated future cash flows, or both. Each situation is different—how we arrive at an estimate of fair value will reflect the peculiarities of each situation. Once we estimate fair value, we ask a number of questions that help us build conviction that current value will be safeguarded and, in fact, increased over time. For example, we want management that is capable, properly incentivized and likely to treat fellow shareholders fairly. We also favor companies that have authorized a plan to repurchase their own shares when they are available at a discount to fair value. Repurchases not only provide short-term support for the stock price but, more importantly, boost per-share intrinsic value and signal management’s willingness to return cash to shareholders. Finally, we want companies with strong and liquid balance sheets, enabling their executives to steer through—and take advantage of—difficult economic conditions. You include some stock screens in this report. Are you saying that the companies passing those screens are also good investment opportunities? Not necessarily. We provide three downside protection stock screens in order to identify companies that may represent good investments. We provide the screen results as a starting point from which you may do more research into specific companies. What are the other benefits of subscription in addition to receiving this report? As a subscriber, you have access to the members-only section of manualofideas.com. The section includes an archive of past reports and access to other subscriber-only content. WE’VE BEEN CALLED MANY THINGS. BUT WE’RE NOT COMPLAINING. “INVALUABLE.” “IMPRESSIVE.” “INCREDIBLE.” “TREASURE TROVE.” “WINNER.” “The Manual of Ideas is a tremendous effort and very well put together.” —MOHNISH PABRAI, MANAGING PARTNER, PABRAI INVESTMENT FUNDS “Invaluable tool for the serious investor.” —TIM DAVIS, MANAGING DIRECTOR, BLUESTEM ASSET MANAGEMENT “We do similar work ourselves.” —GLENN GREENBERG, MANAGING DIRECTOR, CHIEFTAIN CAPITAL MGMT “Outstanding.” —JONATHAN HELLER, EDITOR, CHEAP STOCKS “The best institutional-quality equity research to come along in a long time.” —PAVEL SAVOR, ASSISTANT PROFESSOR OF FINANCE, THE WHARTON SCHOOL “One of my must-read sources.” —CORY JANSSEN, FOUNDER, INVESTOPEDIA.COM “Wonderful.” —TOM GAYNER, CHIEF INVESTMENT OFFICER, MARKEL CORPORATION FIND OUT WHAT THE BUZZ IS ABOUT. WWW.MANUALOFIDEAS.COM
Start 30-day FREE trial of Downside Protection Report .